The Echelon-2 Trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A plus CHP) Vs CHOP in frontline treatment of pts with CD30-positive peripheral t-cell lymphoma
Authors
Horwitz, S. M.Savage, K. J.
Illidge, Timothy M
Plyer, S.
Advani, R.
Shustov, A. R.
Bartlett, N. L.
Pro, B.
Jacobsen, E. D.
Koch, R.
Eva, D. D.
Fanale, M. A.
Fenton, K.
Campana, F.
Dong, C.
Truemper, L.
Affiliation
Memorial Sloan Kettering Cancer Service, Basking Ridge, NJIssue Date
2021
Metadata
Show full item recordCitation
Horwitz SM, Savage KJ, Timillidge, Plyer S, Advani R, Shustov AR, et al. The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398800133.Journal
BloodDOI
10.1182/blood-2021-145124Additional Links
https://dx.doi.org/10.1182/blood-2021-145124Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-145124